Personalis Management

Management Kriterienprüfungen 1/4

Personalis' CEO ist Chris Hall , ernannt in Dec 2022, hat eine Amtszeit von 1.5 Jahren. Die jährliche Gesamtvergütung beträgt $1.73M , bestehend aus 30.9% Gehalt und 69.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.069% der Aktien des Unternehmens, im Wert von €42.83K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 2 Jahre.

Wichtige Informationen

Chris Hall

Geschäftsführender

US$1.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	30.9%
Amtszeit als Geschäftsführer	1.5yrs
Eigentum des Geschäftsführers	0.07%
Durchschnittliche Amtszeit des Managements	2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chris Hall im Vergleich zu den Einnahmen von Personalis verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$93m
Dec 31 2023	US$2m	US$534k	-US$108m
Sep 30 2023	n/a	n/a	-US$113m
Jun 30 2023	n/a	n/a	-US$110m
Mar 31 2023	n/a	n/a	-US$114m
Dec 31 2022	US$2m	US$83k	-US$113m

Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD1.73M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD408.13K).

Entschädigung vs. Einkommen: ChrisDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Chris Hall (55 yo)

1.5yrs

Amtszeit

US$1,726,790

Vergütung

Mr. Christopher M. Hall, also known as Chris, served as Senior Vice President and Head of Diagnostics Business at Personalis, Inc. since October 2022 until December 31, 2022 and serves as its President sin...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Hall	President	1.5yrs	US$1.73m	0.069% $ 41.1k
Aaron Tachibana	CFO & COO	5.3yrs	US$1.67m	0.30% $ 176.7k
Stephen Moore	Senior VP & Chief Legal Officer	4.2yrs	US$674.28k	0.13% $ 79.3k
Richard Chen	Executive VP of R&D and Chief Medical Officer	2.9yrs	US$1.28m	0.20% $ 121.3k
Russ Altman	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	keine Daten	keine Daten
Euan Ashley	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	keine Daten	keine Daten
Michael Snyder	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	keine Daten	keine Daten
Michael Fitzpatrick	Vice President of Worldwide Sales	11.2yrs	keine Daten	keine Daten
Christian Haudenschild	Senior Vice President of Genomic Laboratory Operations	2.8yrs	keine Daten	keine Daten
Stephane Mouradian	Senior Vice President of Business Development	1.4yrs	keine Daten	keine Daten
Deepshikha Bhandari	Senior Vice President of Regulatory	less than a year	keine Daten	keine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: 04XDas Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christopher Hall	President	1.3yrs	US$1.73m	0.069% $ 41.1k
Russ Altman	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	keine Daten	keine Daten
Euan Ashley	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	keine Daten	keine Daten
Michael Snyder	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	keine Daten	keine Daten
Kenneth Widder	Independent Director	less than a year	US$154.00k	keine Daten
Karin Eastham	Independent Chair of the Board	4.8yrs	US$173.05k	0.026% $ 15.5k
Arthur Bowman	Independent Director	5.1yrs	US$121.38k	0.026% $ 15.5k
Woodrow Myers	Independent Director	3.3yrs	US$108.88k	0.050% $ 30.0k
John West	Advisor to the Board	1.5yrs	US$5.62m	0% $ 0
Lonnie Shoff	Independent Director	1.8yrs	US$103.88k	0.020% $ 11.8k
Olivia Bloom	Independent Director	2.3yrs	US$116.38k	0.034% $ 20.2k

2.0yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: 04XDie Vorstandsmitglieder gelten nicht als erfahren ( 2 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Personalis Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Personalis, Inc., Annual General Meeting, May 17, 2024

Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis, Inc. Announces Board Changes

High number of new directors

Personalis, Inc. Announces Retirement of John West from the Board of Directors

Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business

Recent updates

Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)

Personalis, Inc. to Report Q1, 2024 Results on May 08, 2024

Personalis, Inc., Annual General Meeting, May 17, 2024

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring

Full year 2023 earnings released: US$2.25 loss per share (vs US$2.48 loss in FY 2022)

Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Personalis, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay

Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Personalis, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.58 loss in 3Q 2022)

Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Personalis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study

Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

New minor risk - Shareholder dilution

Personalis, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.60 loss in 2Q 2022)

Personalis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Personalis, Inc. Announces Board Changes

High number of new directors

First quarter 2023 earnings released: US$0.61 loss per share (vs US$0.63 loss in 1Q 2022)

Personalis, Inc. Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: US$2.48 loss per share (vs US$1.49 loss in FY 2021)

Personalis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Personalis, Inc. Announces Retirement of John West from the Board of Directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business

Personalis, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.34 loss in 2Q 2021)

Personalis, Inc. Provides Earnings Guidance for the Year 2022

Personalis, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Personalis, Inc.(NasdaqGM:PSNL) dropped from Russell 2000 Growth Index

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.29 loss in 1Q 2021)

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

High number of new directors

Personalis, Inc. to Report Q1, 2022 Results on May 04, 2022

Personalis Announces Issuance of Additional US Patent Related to the Next Personal Platform

Personalis, Inc., Annual General Meeting, May 17, 2022

High number of new directors

No longer forecast to breakeven

Personalis, Inc. Provides Earnings Guidance for the Full Year 2022

Forecast to breakeven in 2024

Personalis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021

Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.27 loss in 3Q 2020)

Senior VP & CFO recently sold €57k worth of stock

Chief Financial Officer recently sold €71k worth of stock

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.29 loss in 2Q 2020)

Chief Financial Officer recently sold €51k worth of stock

Independent Director has left the company

Personalis, Inc. Provides Financial Guidance for the Second Quarter and Full Year of 2021

First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2020)

Chief Financial Officer recently sold €55k worth of stock

Personalis, Inc. Announces Board Changes

Chief Financial Officer recently sold €82k worth of stock

Independent Director has left the company

New 90-day low: €22.00

Revenue beats expectations

Full year 2020 earnings released: US$1.20 loss per share (vs US$1.39 loss in FY 2019)

Natera, Inc. and Personalis, Inc. Partner for Personalized Monitoring in Oncology

Personalis, Inc. Announces Appointment of Susan Moriconi as VP of People and Chief Human Resources Officer

Analyse der Geschäftsführervergütung

Geschäftsführer